Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency

EJHaem Pub Date : 2024-07-11 DOI:10.1002/jha2.972
Julien Dereme, Matthew Goodyer, David Baud, Lorenzo Alberio, Francesco Grandoni, Mathilde Gavillet
{"title":"Targeted management of coexistent severe thrombophilias—A case report of a successful pregnancy despite paroxysmal nocturnal hemoglobinuria and hereditary protein C deficiency","authors":"Julien Dereme,&nbsp;Matthew Goodyer,&nbsp;David Baud,&nbsp;Lorenzo Alberio,&nbsp;Francesco Grandoni,&nbsp;Mathilde Gavillet","doi":"10.1002/jha2.972","DOIUrl":null,"url":null,"abstract":"<p>Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by the absence of complement regulatory proteins on the surface of erythrocytes, leading to intravascular hemolysis and thrombosis. Managing PNH during pregnancy poses significant challenges due to increased risks of morbidity and mortality. This case report describes the detailed obstetric course of a 44-year-old woman with PNH and additional hereditary protein C deficiency who had previously experienced multiple thrombotic events and adverse pregnancy outcomes (two early miscarriages and one stillbirth at 25 weeks gestation [WG]), treated with eculizumab (terminal C5 inhibitor) and optimal anticoagulation management. Close monitoring of hemolysis and hemostasis parameters was conducted throughout the gestation period together with increased obstetrical surveillance. The pregnancy progressed without thrombotic complications or breakthrough hemolysis, and the patient delivered a healthy newborn at 36 WG after induction of labor due to restricted fetal growth. To the best of our knowledge, this is the first reported case of a positive pregnancy outcome despite PNH in conjunction with hereditary thrombophilia. This case report highlights the importance of a multidisciplinary approach involving hematologists and obstetricians in the management of pregnant women with PNH. Tailored therapy, close monitoring, and comprehensive care are crucial to minimize risks and optimize outcomes.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"5 5","pages":"1048-1052"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.972","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.972","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematological disorder characterized by the absence of complement regulatory proteins on the surface of erythrocytes, leading to intravascular hemolysis and thrombosis. Managing PNH during pregnancy poses significant challenges due to increased risks of morbidity and mortality. This case report describes the detailed obstetric course of a 44-year-old woman with PNH and additional hereditary protein C deficiency who had previously experienced multiple thrombotic events and adverse pregnancy outcomes (two early miscarriages and one stillbirth at 25 weeks gestation [WG]), treated with eculizumab (terminal C5 inhibitor) and optimal anticoagulation management. Close monitoring of hemolysis and hemostasis parameters was conducted throughout the gestation period together with increased obstetrical surveillance. The pregnancy progressed without thrombotic complications or breakthrough hemolysis, and the patient delivered a healthy newborn at 36 WG after induction of labor due to restricted fetal growth. To the best of our knowledge, this is the first reported case of a positive pregnancy outcome despite PNH in conjunction with hereditary thrombophilia. This case report highlights the importance of a multidisciplinary approach involving hematologists and obstetricians in the management of pregnant women with PNH. Tailored therapy, close monitoring, and comprehensive care are crucial to minimize risks and optimize outcomes.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
并存的严重血栓性疾病的针对性治疗--一例在阵发性夜间血红蛋白尿和遗传性蛋白 C 缺乏症的情况下成功怀孕的病例报告
阵发性夜间血红蛋白尿症(PNH)是一种罕见的血液病,其特点是红细胞表面缺乏补体调节蛋白,从而导致血管内溶血和血栓形成。由于发病率和死亡率风险增加,妊娠期 PNH 的治疗面临巨大挑战。本病例报告详细描述了一名 44 岁女性的产科病程,她患有 PNH 和额外的遗传性蛋白 C 缺乏症,之前曾经历过多次血栓事件和不良妊娠结局(两次早期流产和一次妊娠 25 周死胎 [WG]),在接受了依库珠单抗(末端 C5 抑制剂)治疗和最佳抗凝管理后,她的病情得到了控制。在整个妊娠期对溶血和止血参数进行了密切监测,并加强了产科监护。由于胎儿生长受限,患者在引产后 36 WG 时娩出了一名健康的新生儿。据我们所知,这是首例在 PNH 并发遗传性血栓性疾病的情况下仍取得良好妊娠结果的病例。本病例报告强调了由血液科医生和产科医生共同参与的多学科方法在治疗 PNH 孕妇中的重要性。量身定制的治疗、严密的监测和全面的护理对于最大限度地降低风险和优化预后至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Terminal deoxynucleotidyl transferase-positive high-grade B-cell lymphoma with MYC and BCL2 rearrangements transformed from follicular lymphoma Enteropathy-associated T-cell lymphoma: A population-based cohort study on incidence, treatment, and outcome in the Netherlands Low-dose nivolumab for extranodal natural killer/T-cell lymphoma, nasal type IFN-α treatment may enable discontinuation of TKIs in NK cell-licensed patients with CML-CP
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1